Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020198063 - ADMINISTRATION OF EICOSAPENTAENOIC ACID AND ITS DERIVATIVES TO CORRECT THE SUSCEPTIBILITY OF APOB-LIPOPROTEINS AGGREGATION

Publication Number WO/2020/198063
Publication Date 01.10.2020
International Application No. PCT/US2020/024020
International Filing Date 20.03.2020
IPC
A61K 31/202 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
20having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
202having three or more double bonds, e.g. linolenic acid
A61K 31/40 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
Applicants
  • WILLIAMS, Kevin, Jon [US]/[US]
Inventors
  • WILLIAMS, Kevin, Jon
Agents
  • FRIED, Allan, H.
Priority Data
62/824,62827.03.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ADMINISTRATION OF EICOSAPENTAENOIC ACID AND ITS DERIVATIVES TO CORRECT THE SUSCEPTIBILITY OF APOB-LIPOPROTEINS AGGREGATION
(FR) ADMINISTRATION D'ACIDE EICOSAPENTAÉNOÏQUE ET DE SES DÉRIVÉS POUR CORRIGER LA SUSCEPTIBILITÉ D'UNE AGRÉGATION DE LIPOPROTÉINES APOB
Abstract
(EN)
Methods, systems and kits for treating selected patients with eicosapentaenoic acid and its derivatives, especially icosapent ethyl, in order to correct the susceptibility of apoB-lipoproteins to aggregation in the presence of secretory sphingomyelinase and thereby achieve effective treatment.
(FR)
L'invention concerne des procédés, des systèmes et des kits pour traiter des patients sélectionnés avec de l'acide eicosapentaénoïque et ses dérivés, en particulier l'icosapentéthyle, afin de corriger la susceptibilité de lipoprotéines apoB à une agrégation en présence de sphingomyélinase sécrétoire et ainsi d'obtenir un traitement efficace.
Latest bibliographic data on file with the International Bureau